Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

EMA Approves First Ustekinumab Biosimilar, Uzpruvo

January 10th 2024

By Skylar Jeremias

Article

The European Medicines Agency (EMA) has granted marketing authorization to the first ustekinumab biosimilar, STADA Arzneimittel and Alvotech’s Uzpruvo.

IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe

January 10th 2024

By Skylar Jeremias

Article

IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.

Examining Attitudes in German, Swiss Pharmacists on Biosimilar Dispensing Pre- and Post Pandemic

January 9th 2024

By Cameron Santoro

Article

A recent study found that the COVID-19 pandemic had little impact on the knowledge and attitudes of German and Swiss pharmacists regarding biologics and biosimilars between 2020 and 2022.

BioRationality: An Analysis of the Future of Biosimilars Through the Eyes of History

January 8th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarafraz K. Niazi, PhD, previews the new year and his hopes for the end of clinical efficacy testing for biosimilar approvals using examples from history of other scientific concepts that took time to gain traction.

Quiz: The Basics of Biosimilars

January 8th 2024

By The Center for Biosimilars Staff

Article

Intro to Biosimilars is now in session! Test yourself on how well you know these biosimilar basics.

Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars

January 7th 2024

By Brooke McCormick

Video

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.

CVS to Remove Humira From Some Reimbursement Lists in Favor of Biosimilar Options

January 6th 2024

Article

Starting April 1, 2024, Hyrimoz and an unbranded version of Humira manufactured by Sandoz will be covered across all CVS formularies.

The Top 5 Biosimilar Articles for the Week of January 1

January 5th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 1, 2024.

Posters Show Efficacy for Combination Therapies With Trastuzumab Biosimilars in Breast Cancer

January 4th 2024

By Skylar Jeremias

Article

Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.

Biosimilar SB5 Matches Originator in Safety, Efficacy for Inflammatory Diseases After Switching

January 3rd 2024

By Cameron Santoro

Article

Adults with inflammatory diseases maintained disease control when transitioning from originator adalimumab (Humira) to biosimilar SB5 in a pan-European study.